Intelligence Feed event · Macro · 2026-10-01

    Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial

    Question

    Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial

    Direct answer

    Top-line data from the Phase III SYNCHRONIZE-2 trial showed Boehringer Ingelheim and Zealand Pharma's dual glucagon/GLP-1 receptor agonist survodutide achieved up to 13.1% body weight reduction after 76 weeks, compared to 3.1% in the placebo group. The study evaluated patients with obesity and type 2 diabetes, a demographic where weight loss is typically harder to achieve, while demonstrating substantial improvements in blood glucose markers.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/boehringer-and-zealand-report-13-1-weight-loss-in-survodutide-phase-iii-trial-d67e7b

    MACRO
    Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial
    Top-line data from the Phase III SYNCHRONIZE-2 trial showed Boehringer Ingelheim and Zealand Pharma's dual glucagon/GLP-1 receptor agonist survodutide achieved up to 13.1% body weight reduction after 76 weeks, compared to 3.1% in the placebo group. The study evaluated patients with obesity and type 2 diabetes, a demographic where weight loss is typically harder to achieve, while demonstrating substantial improvements in blood glucose markers.
    ZLDPY
    Impact
    76
    OCT 1
    SIG
    92%
    ZLDPY
    Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial
    Top-line data from the Phase III SYNCHRONIZE-2 trial showed Boehringer Ingelheim and Zealand Pharma's dual glucagon/GLP-1 receptor agonist survodutide achieved up to 13.1% body weight reduction after 76 weeks, compared to 3.1% in the placebo group. The study evaluated patients with obesity and type 2 diabetes, a demographic where weight loss is typically harder to achieve, while demonstrating substantial improvements in blood glucose markers.
    → Phase III metabolic trial validation de-risks commercialization timelines, driving milestone and royalty net present value upward for Zealand Pharma (ZLDPY).
    Impact
    Top-line data from the Phase III SYNCHRONIZE-2 trial showed Boehringer Ingelheim and Zealand Pharma's dual glucagon/GLP-1 receptor agonist survodutide achieved up to 13.1% body weight reduction after 76 weeks, compared to 3.1% in the placebo group. The study evaluated patients with obesity and type 2 diabetes, a demographic where weight loss is typically harder to achieve, while demonstrating substantial improvements in blood glucose markers.
    Affected
    ZLDPY
    Transmission
    Phase III metabolic trial validation de-risks commercialization timelines, driving milestone and royalty net present value upward for Zealand Pharma (ZLDPY).

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYroyalty revenue and milestone payment repricing upon Phase III clinical successUp1-5dZealand Pharma co-invented survodutide and is entitled to milestones and tiered royalties.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month